Bliss GVS Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bliss GVS Pharma Ltd. on BSE

Load latest

Bliss GVS Pharma Ltd.

06 Dec 2024

154.42

1.13%

Corp. Note

BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate …

BSE India

Enclosed herewith the details of loss of share certificates.

pdf

Bliss GVS Pharma Ltd.

23 Nov 2024

154.42

1.13%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Intimation Regarding Certificate Of EU GMP Compliance For Company'S …

BSE India

Dear Sir/Madam, Pursuant to Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Company''s manufacturing facility situated at Plot. No. 11, Dewan Udyog Nagar, Aliyali Village, Palghar, 401404 India, and Survey No. 43-44, Vevoor Village, 401404, India has successfully received a Certificate of GMP(Good Manufacturing Practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR) following an EU GMP inspection that took place on 30th November and 1st December 2023.

pdf

Bliss GVS Pharma Ltd.

15 Nov 2024

154.42

1.13%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

We like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on November 15, 2024, has approved the allotment of 30,000 equity shares of the face value of Re. 1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 (''Bliss GVS ESOP - 2019'').

pdf

Bliss GVS Pharma Ltd.

07 Nov 2024

154.42

1.13%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations …

BSE India

Pursuant to the provisions of Regulation 30 read with sub-para 20, Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby submit the disclosure regarding Audit observation letter imposing GST Liability with interest & penalty against the Company. Enclosed herewith disclosure under Reg. 30 of the SEBI Listing Regulations.

pdf

Bliss GVS Pharma Ltd.

30 Oct 2024

154.42

1.13%

SAST

BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narsimha Shibroor Kamath & PACs

pdf

Bliss GVS Pharma Ltd.

30 Oct 2024

154.42

1.13%

SAST

BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narsimha Shibroor Kamath & PACs

pdf

Bliss GVS Pharma Ltd.

28 Oct 2024

154.42

1.13%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Enclosed herewith the copies of the newspaper advertisement published regarding the extract of the statement of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024.

pdf

Bliss GVS Pharma Ltd.

24 Oct 2024

154.42

1.13%

Board Meeting

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Outcome for Outcome Of Board Meeting Held …

BSE India

Please find the attached Outcome of Board Meeting held on Thursday, October 24, 2024.

pdf

Bliss GVS Pharma Ltd.

17 Oct 2024

154.42

1.13%

Board Meeting

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial …

BSE India

BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30, 2024 Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30, 2024

pdf

Bliss GVS Pharma Ltd.

17 Oct 2024

154.42

1.13%

Board Meeting

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial …

BSE India

pdf

Is Bliss GVS Pharma Ltd. worth buying?

169 Votes:

Buy 81.07%

Sell 8.88%

Hold 10.06%